What is Aptevo Therapeutics Debt-to-Equity?
Aptevo Therapeutics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $0.00 Mil. Aptevo Therapeutics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $5.21 Mil. Aptevo Therapeutics's Total Stockholders Equity for the quarter that ended in Mar. 2024 was $6.10 Mil.
Aptevo Therapeutics's debt to equity for the quarter that ended in Mar. 2024 was 0.85.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Aptevo Therapeutics's Debt-to-Equity or its related term are showing as below:
APVO'
s Debt-to-Equity Range Over the Past 10 Years
Min: -1 Med: 0.44 Max: 13.75
Current: 0.85
During the past 11 years, the highest Debt-to-Equity Ratio of Aptevo Therapeutics was 13.75. The lowest was -1.00. And the median was 0.44.
Aptevo Therapeutics Debt-to-Equity Historical Data
The historical data trend for Aptevo Therapeutics's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Aptevo Therapeutics Debt-to-Equity Chart
|
Aptevo Therapeutics Annual Data
|
|
Trend |
Dec14 |
Dec15 |
Dec16 |
Dec17 |
Dec18 |
Dec19 |
Dec20 |
Dec21 |
Dec22 |
Dec23 |
| Debt-to-Equity |
|
Get a 7-Day Free Trial
|
|
|
1.96 |
1.65 |
13.75 |
0.53 |
0.44 |
|
Aptevo Therapeutics Quarterly Data
|
|
Jun19 |
Sep19 |
Dec19 |
Mar20 |
Jun20 |
Sep20 |
Dec20 |
Mar21 |
Jun21 |
Sep21 |
Dec21 |
Mar22 |
Jun22 |
Sep22 |
Dec22 |
Mar23 |
Jun23 |
Sep23 |
Dec23 |
Mar24 |
| Debt-to-Equity |
Get a 7-Day Free Trial
|
|
|
|
|
|
|
|
|
|
|
|
|
0.25 |
0.35 |
0.38 |
0.44 |
0.85 |
Competitive Comparison of Aptevo Therapeutics's Debt-to-Equity
For the Biotechnology subindustry, Aptevo Therapeutics's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aptevo Therapeutics's Debt-to-Equity Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Aptevo Therapeutics's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Aptevo Therapeutics's Debt-to-Equity falls into.
Aptevo Therapeutics Debt-to-Equity Calculation
Debt to Equity measures the financial leverage a company has.
Aptevo Therapeutics's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as
Aptevo Therapeutics's Debt to Equity Ratio for the quarter that ended in Mar. 2024 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Aptevo Therapeutics (Aptevo Therapeutics) Business Description
Traded in Other Exchanges
Address
2401 4th Avenue, Suite 1050, Seattle, WA, USA, 98121
Aptevo Therapeutics Inc is a clinical-stage, research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidate, APVO436, and preclinical candidates, ALG.APV-527 and APVO603, were developed using ADAPTIR modular protein technology platform. The versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.
Executives
| Daphne Taylor |
officer: SVP, CFO |
3303 MONTE VILLA PARKWAY, BOTHELL WA 98021 |
| Kevin C Tang |
10 percent owner |
4747 EXECUTIVE DRIVE, SUITE 210, SAN DIEGO CA 92121 |
| Soyoung Kwon |
officer: See Remarks |
APTEVO THERAPEUTICS INC., 2401 4TH AVENUE, SUITE 1050, SEATTLE WA 98121 |
| Tang Capital Management Llc |
10 percent owner |
4747 EXECUTIVE DRIVE, SUITE 210, SAN DIEGO CA 92121 |
| Tang Capital Partners Lp |
10 percent owner |
4747 EXECUTIVE DRIVE, SUITE 210, SAN DIEGO CA 92121 |
| Randy Joe Maddux |
officer: Senior VP, Operations |
2401 4TH AVENUE, SUITE #1050, SEATTLE WA 98121 |
| Fuad El-hibri |
director |
2273 RESEARCH BLVD, SUITE 400, ROCKVILLE MD 20850 |
| Daniel Abdun-nabi |
director |
400 PROFESSIONAL DRIVE, SUITE 400, GAITHERSBURG MD 20879 |
| Marvin L White |
director, officer: President and CEO |
2273 RESEARCH BLVD, SUITE 400, ROCKVILLE MD 20850 |
| Barbara Lopez Kunz |
director |
2401 4TH AVENUE, SUITE 1050, SEATTLE WA 98121 |
| Zsolt Harsanyi |
director |
2273 RESEARCH BLVD., SUITE 400, ROCKVILLE MD 20850 |
| Grady Iii Grant |
director |
2401 4TH AVENUE, SUITE 1050, SEATTLE WA 98121 |
| Shawnte Mitchell |
officer: SVP, GC and Corporate Affairs |
5959 HORTON STREET, SUITE 500, EMERYVILLE CA 94608 |
| Michael Adelman |
officer: SVP, Commercial Operations |
2401 4TH AVENUE, SUITE 1050, SEATTLE WA 98121 |
| Jane A Gross |
officer: See Remarks |
2401 4TH AVENUE, SUITE 1050, SEATTLE WA 98121 |
Aptevo Therapeutics (Aptevo Therapeutics) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
APVO has been successfully added to your